Resolution of orbitocerebral aspergillosis during combination treatment with voriconazole and amphotericin plus adjunctive cytokine therapy.
Orbitocerebral aspergillosis has a very high fatality rate and cure is unusual. We describe the successful management of a child with cereberal aspergillosis who had a dramatic response to therapy with a combination of liposomal amphotericin and voriconazole with adjunctive cytokine therapy during immunosuppresive chemotherapy for acute lymphoblastic leukaemia.
Bethell
Delia
D
Department of Paediatrics, John Radcliffe Hospital, Oxford, United Kingdom.
Hall
Georgina
G
Goodman
T Robin
TR
Klein
Nigel
N
Pollard
Andrew J
AJ
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001766:Blindness / Q000209:etiology; D001927:Brain Diseases / Q000382:microbiology; D002675:Child, Preschool; D016207:Cytokines / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D020953:Neuroaspergillosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction / Q000379:methods; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D016207:Cytokines; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D065819:Voriconazole